Abbott Laboratories (NYSE:ABT) EVP Daniel Gesua Sive Salvadori sold 96,603 shares of the stock in a transaction that occurred on Monday, October 23rd. The stock was sold at an average price of $56.21, for a total transaction of $5,430,054.63. Following the transaction, the executive vice president now owns 142,082 shares in the company, valued at approximately $7,986,429.22. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Daniel Gesua Sive Salvadori also recently made the following trade(s):

  • On Tuesday, September 26th, Daniel Gesua Sive Salvadori sold 62,460 shares of Abbott Laboratories stock. The stock was sold at an average price of $52.95, for a total transaction of $3,307,257.00.

Shares of Abbott Laboratories (NYSE:ABT) traded up 0.20% during trading on Wednesday, reaching $55.49. 6,112,954 shares of the company traded hands. The firm’s 50-day moving average is $53.46 and its 200-day moving average is $48.75. The stock has a market capitalization of $96.41 billion, a PE ratio of 77.72 and a beta of 1.06. Abbott Laboratories has a 12-month low of $37.38 and a 12-month high of $56.69.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Wednesday, October 18th. The healthcare product maker reported $0.66 EPS for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.01. Abbott Laboratories had a net margin of 8.37% and a return on equity of 14.50%. The business had revenue of $6.83 billion during the quarter, compared to analysts’ expectations of $6.72 billion. During the same quarter in the previous year, the company earned $0.59 EPS. The business’s quarterly revenue was up 28.8% compared to the same quarter last year. On average, equities analysts predict that Abbott Laboratories will post $2.50 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Wednesday, November 15th. Investors of record on Friday, October 13th will be issued a dividend of $0.265 per share. The ex-dividend date is Thursday, October 12th. This represents a $1.06 dividend on an annualized basis and a yield of 1.91%. Abbott Laboratories’s dividend payout ratio is currently 83.47%.

COPYRIGHT VIOLATION WARNING: This piece was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/25/daniel-gesua-sive-salvadori-sells-96603-shares-of-abbott-laboratories-abt-stock.html.

A number of large investors have recently bought and sold shares of the stock. Vanguard Group Inc. raised its holdings in Abbott Laboratories by 2.6% during the 2nd quarter. Vanguard Group Inc. now owns 129,786,955 shares of the healthcare product maker’s stock valued at $6,308,944,000 after buying an additional 3,241,063 shares during the last quarter. State Street Corp raised its holdings in Abbott Laboratories by 18.9% during the 1st quarter. State Street Corp now owns 80,499,469 shares of the healthcare product maker’s stock valued at $3,574,987,000 after buying an additional 12,806,535 shares during the last quarter. Capital Research Global Investors raised its holdings in Abbott Laboratories by 45.7% during the 2nd quarter. Capital Research Global Investors now owns 47,589,663 shares of the healthcare product maker’s stock valued at $2,313,334,000 after buying an additional 14,918,038 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in Abbott Laboratories by 11.0% during the 1st quarter. Bank of New York Mellon Corp now owns 33,796,869 shares of the healthcare product maker’s stock valued at $1,500,920,000 after buying an additional 3,344,508 shares during the last quarter. Finally, Northern Trust Corp raised its holdings in Abbott Laboratories by 3.1% during the 2nd quarter. Northern Trust Corp now owns 26,865,706 shares of the healthcare product maker’s stock valued at $1,305,942,000 after buying an additional 809,732 shares during the last quarter. Institutional investors own 71.42% of the company’s stock.

ABT has been the topic of a number of analyst reports. Royal Bank Of Canada restated a “buy” rating and set a $55.00 target price on shares of Abbott Laboratories in a research report on Tuesday, October 3rd. Jefferies Group LLC restated a “buy” rating and set a $58.00 target price on shares of Abbott Laboratories in a research report on Thursday, June 29th. TheStreet upgraded shares of Abbott Laboratories from a “c+” rating to a “b” rating in a research report on Monday, July 3rd. Wells Fargo & Company restated an “outperform” rating and set a $54.00 target price (up previously from $47.50) on shares of Abbott Laboratories in a research report on Friday, June 30th. Finally, Cowen and Company restated an “outperform” rating and set a $55.00 target price (up previously from $48.00) on shares of Abbott Laboratories in a research report on Friday, July 14th. Seven equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $56.81.

About Abbott Laboratories

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Insider Buying and Selling by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.